This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

• Narrative Content
• XML
• JSON

: Mirvetuximab soravtansine

Raw json | Download

{
  "resourceType" : "MedicationRequest",
  "id" : "mii-exa-mtb-medication-request-mirvetuximab",
  "meta" : {
    "profile" : [
      🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung|2027.0.0-ballot.1"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "extensions",
    "div" : "<div xml:lang=\"en\" lang=\"en\"><hr/><p><b>English</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: MedicationRequest mii-exa-mtb-medication-request-mirvetuximab</b></p><a name=\"mii-exa-mtb-medication-request-mirvetuximab\"> </a><a name=\"hcmii-exa-mtb-medication-request-mirvetuximab\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-mtb-therapieempfehlung.html\">MII PR MTB Therapieempfehlung Systemische Therapie</a> version: 2027.0.0-ballot.1</p></div><p><b>MII EX MTB Empfehlung Priorität</b>: 1</p><p><b>MII EX MTB Empfehlung Evidenzgraduierung</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad m1A}\">Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.</span></p><p><b>MII EX MTB Empfehlung Publikation</b>: <code>http://doi.org</code>/10.1200/JCO.2022.40.16_suppl.5512</p><p><b>MII EX MTB Empfehlung Publikation</b>: <code>http://www.ncbi.nlm.nih.gov/pubmed</code>/38055253</p><p><b>status</b>: Completed</p><p><b>intent</b>: Proposal</p><p><b>medication</b>: <span title=\"Codes:{http://fdasis.nlm.nih.gov 98DE7VN88D}, {http://fhir.de/CodeSystem/bfarm/atc L01FX26}, {http://fhir.de/CodeSystem/bfarm/atc L01FX}\">MIRVETUXIMAB SORAVTANSINE</span></p><p><b>subject</b>: <a href=\"Patient-PatientKimMusterperson.html\">Kim Musterperson  (no stated gender), DoB: 1956-03-14</a></p><p><b>authoredOn</b>: 2023-03-28</p><p><b>reasonReference</b>: <a href=\"Condition-PatientKimMusterperson-PrimaryDiagnosis-2.html\">Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet</a></p><p><b>basedOn</b>: <a href=\"CarePlan-mii-exa-mtb-kim-musterperson-therapieplan.html\">CarePlan: status = active; intent = plan; category = prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie); created = 2023-03-28</a></p></div>"
  },
  "extension" : [
    {
      "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-prioritaet",
      "valuePositiveInt" : 1
    },
    {
      "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-evidenzgraduierung",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad",
            "code" : "m1A"
          }
        ]
      }
    },
    {
      "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-publikation",
      "valueIdentifier" : {
        "system" : "http://doi.org",
        "value" : "10.1200/JCO.2022.40.16_suppl.5512"
      }
    },
    {
      "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-publikation",
      "valueIdentifier" : {
        "system" : "http://www.ncbi.nlm.nih.gov/pubmed",
        "value" : "38055253"
      }
    }
  ],
  "status" : "completed",
  "intent" : "proposal",
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://fdasis.nlm.nih.gov",
        "code" : "98DE7VN88D",
        "display" : "MIRVETUXIMAB SORAVTANSINE"
      },
      {
        "system" : "http://fhir.de/CodeSystem/bfarm/atc",
        "version" : "2025",
        "code" : "L01FX26",
        "display" : "Mirvetuximab soravtansin"
      },
      {
        "system" : "http://fhir.de/CodeSystem/bfarm/atc",
        "version" : "2025",
        "code" : "L01FX",
        "display" : "Andere monoklonale Antikörper und Antikörper-Wirkstoff-Konjugate"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/PatientKimMusterperson"
  },
  "authoredOn" : "2023-03-28",
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/PatientKimMusterperson-PrimaryDiagnosis-2"
    }
  ],
  "basedOn" : [
    {
      🔗 "reference" : "CarePlan/mii-exa-mtb-kim-musterperson-therapieplan"
    }
  ]
}